Abramson Cancer Center at Penn Medicine
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Abramson Cancer Center at Penn Medicine sits in the top decile of US sponsors by registered trial count (#92 of 15,742 sponsors by registered trial count).
Abramson Cancer Center at Penn Medicine: 402 sponsored US clinical trials, 74 recruiting.
Abramson Cancer Center at Penn Medicine sponsors 402 registered US clinical trials on ClinicalTrials.gov, 74 of them currently recruiting, and 235 completed. 3 of these trials are in Phase 3-4 (later-stage) and 175 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 20 trials.
Top-decile sponsor footprint
Abramson Cancer Center at Penn Medicine ranks in the top decile of sponsors by registered trial count (#92 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
235 of 280 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
402 total, page 7 of 9
Radvax™: A Stratified Phase I/II Dose Escalation Trial OF Hypofractionated Radiotherapy Followed BY Ipilimumab IN Metastatic Melanoma
NCT01497808
BETERNet Notch Signaling and Novel Biomarkers for Barretts Esophagus
NCT01484925
A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia
NCT01486784
Brivanib Metastatic Renal Cell Carcinoma
NCT01253668
Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma
NCT01510119
Proton Radiotherapy for Upper Gastrointestinal Malignancies
NCT01449864
Experience of Non-Melanoma Skin Cancer (NMSC) Mohs Surgery Project
NCT01452984
Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT01796041
Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine
NCT01396200
Pelvic Floor Disorders in Survivors of Gynecologic Malignancies
NCT01370122
Cardiovascular Effects of Sunitinib Therapy (CREST)
NCT01370109
A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT01312389
F18 EF5 PET/CT Imaging in Patients With Brain Metastases From Breast Cancer
NCT01985971
PD0332991/Paclitaxel in Advanced Breast Cancer
NCT01320592
Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer
NCT01312376
Effect of Donepezil on Smoking
NCT01250977
The Effects of Radiation in Reconstructed Breasts
NCT01292772
DIBH Proton Planning
NCT01386697
Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)
NCT01221506
Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT00568880
A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy
NCT02130427
Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy
NCT01548807
Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
NCT01212731
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
NCT01206530
BCRL Prevention Pilot
NCT01166672
Physical Functional Side Effects of Taxane Chemotherapy for Breast Cancer
NCT01153282
Proton Radiotherapy for Extremity Soft Tissue Sarcoma
NCT01561495
Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)
NCT01113502
Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia
NCT00615784
Autologous OC-DC Vaccine in Ovarian Cancer
NCT01132014
LIVESTRONG Survivorship Care Plan: Continued Data Collection and Follow Up Survey
NCT02559323
Combination Gene Transfer and Chemotherapy
NCT01119664
Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma
NCT01112293
Proton Radiation for Chordomas and Chondrosarcomas
NCT01449149
Proton Beam Radiation With Concurrent Chemotherapy and Nelfinavir for Inoperable Stage III Non Small Cell Lung Cancer (NSCLC)
NCT01108666
Proton Radiation For Meningiomas and Hemangiopericytomas
NCT01117844
Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma
NCT01103635
Proton Radiotherapy for Recurrent Tumors
NCT01126476
Single Nucleotide Polymorphism (SNP) Panels and Risk Assessment in Women Undergoing Mammography
NCT01124019
Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery
NCT01076231
Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas
NCT01024907
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
NCT01037790
Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
NCT01044433
Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer
NCT01042041
Proton Radiation Therapy in Treating Patients With Prostate Cancer
NCT01045226
DC Vaccine for Patients With Ductal Carcinoma In Situ
NCT02061332
Magnetic Resonance Imaging in Evaluating Response to RadiationTherapy in Patients With High Grade Glioma
NCT01018329
Flexitouch Lymphedema System in Treating Stage II Lymphedema in Patients With Breast Cancer
NCT01019512
Magnetic Resonance Imaging-Based Radiation Therapy and Cisplatin in Patients With Stage I, Stage II, Stage III, or Stage IV Cervical Cancer
NCT01016561
Cognitive Behavioral Therapy With or Without Armodafinil in Treating Cancer Survivors With Insomnia and Fatigue After Chemotherapy
NCT01019187
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 113 |
| Phase 2 | 62 |
| Phase 3 | 1 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the Abramson Cancer Center at Penn Medicine pipeline
74 recruiting of 402 indexed (18% open); 235 completed (58%).
Phase mix: 3 late (III/IV) vs 175 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (20 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Abramson Cancer Center at Penn Medicine: open-pipeline peers nationwide
Peers matched on 402 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
Abramson Cancer Center at Penn Medicine sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 402 trials (± recruiting share)
- Case Comprehensive Cancer Center · 407 trials · 14% recruiting
- University of Nebraska · 407 trials · 13% recruiting
- Takeda · 408 trials · 12% recruiting
- University of Kansas Medical Center · 408 trials · 23% recruiting
Sponsors near 18% open enrollment (± trial volume)
- University of Maryland, Baltimore · 18% recruiting · 560 trials
- Henry Ford Health System · 18% recruiting · 234 trials
- New York Institute of Technology · 18% recruiting · 49 trials
- University of California, San Diego · 18% recruiting · 775 trials
Related
What to do with this Abramson Cancer Center at Penn Medicine page
402 registered trials is a research-attention snapshot, not an endorsement of Abramson Cancer Center at Penn Medicine or any single study.
- 74 of Abramson Cancer Center at Penn Medicine's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Abramson Cancer Center at Penn Medicine studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Abramson Cancer Center at Penn Medicine pipeline card: 402 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.